Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 7:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: IV rt-PA Clear all
Completed No phase listed Observational

The PERFusion Use in Stroke Evaluation Study

NCT01387113
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Computed tomography perfusion imaging
Other
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Sep 8, 2026, 7:50 PM EDT
Not listed Phase 1Phase 2 Interventional

Platelet Function in Patients With Ischemic Stroke Treated With Anti-thrombotic or Thrombolytic

NCT05415150
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Thrombolytic Agent
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Phase 2 Interventional Results available

Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)

NCT00061373
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Aspirin, tinzaparin sodium, eptifibatide
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 8, 2026, 7:50 PM EDT
Terminated Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke

NCT02072226
View directory record Official record
Conditions
Stroke
Interventions
Alteplase, Alteplase Placebo, Aspirin, Aspirin Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
88
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Not applicable Interventional Results available

Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial

NCT01657461
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Intravenous (IV) recombinant human tissue plasminogen activator (rtPA), Solitaire revascularization device
Drug · Device
Lead sponsor
Medtronic Neurovascular Clinical Affairs
Industry
Eligibility
18 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Sep 8, 2026, 7:50 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke

NCT01464788
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Low Dose Argatroban, High Dose Argatroban, rt-PA (alteplase)
Drug
Lead sponsor
Andrew D. Barreto, MD
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 8, 2026, 7:50 PM EDT
Terminated Phase 2 Interventional Results available

Feasibility Study of IV Recombinant Tissue Plasminogen Activator (rtPA) vs. Primary Endovascular Therapy for Acute Ischemic Stroke

NCT01869478
View directory record Official record
Conditions
Stroke, Ischemic Stroke
Interventions
Intravenous Thrombolysis, Endovascular Arterial Reperfusion
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Phase 4 Interventional Results available

Assess the Penumbra System in the Treatment of Acute Stroke

NCT01429350
View directory record Official record
Conditions
Ischemic Stroke
Interventions
intravenous (IV) recombinant human tissue plasminogen activator (rtPA), Penumbra System
Drug · Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Denver, Colorado • Gainesville, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Sep 8, 2026, 7:50 PM EDT
Terminated Phase 4 Interventional

A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)

NCT00168792
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Tenecteplase, PCI
Drug · Procedure
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
8
States / cities
Little Rock, Arkansas • Fort Lauderdale, Florida • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2013 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Not applicable Interventional

IV vs. IA tPA (Activase) in Acute Ischemic Stroke With CTA Evidence of Major Vessel Occlusion

NCT00624000
View directory record Official record
Conditions
Ischemic Stroke
Interventions
IV tpa (Alteplase) vs IA tpa (Alteplase)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
19 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

NCT01413542
View directory record Official record
Conditions
Hypertension, Diabetes Type 2
Interventions
Sitagliptin (DPP4 inhibitor), Substance P,, bradykinin, enalaprilat (ACE inhibitor), Glucagon-like peptide 1, brain natriuretic peptide
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke

NCT00630396
View directory record Official record
Conditions
Stroke, Acute
Interventions
Minocycline
Drug
Lead sponsor
David Hess, MD
Other
Eligibility
19 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Lexington, Kentucky • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Phase 2 Interventional Results available

Safety of Intravenous Thrombolysis for Wake-up Stroke

NCT01183533
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Alteplase (iv t-PA)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Birmingham, Alabama • Englewood, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Sep 8, 2026, 7:50 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN)

NCT02180204
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Tenecteplase, Alteplase
Drug
Lead sponsor
Reza Behrouz, DO
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Sep 8, 2026, 7:50 PM EDT
Terminated Phase 3 Interventional Results available

Interventional Management of Stroke (IMS) III Trial

NCT00359424
View directory record Official record
Conditions
Stroke
Interventions
IV rt-PA alone, endovascular therapy
Drug · Other
Lead sponsor
Joseph Broderick
Other
Eligibility
18 Years to 82 Years
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Sep 8, 2026, 7:50 PM EDT
Withdrawn Phase 1 Interventional

Study for the Use of Alteplase in Patients Who Awaken With Stroke

NCT01150266
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Alteplase (tPA)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
22 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Phase 2 Interventional Results available

Safety of Intravenous Thrombolytics in Stroke on Awakening

NCT01643902
View directory record Official record
Conditions
Stroke
Interventions
tPA
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Phase 2 Interventional Results available

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

NCT00894803
View directory record Official record
Conditions
Ischemic Stroke, Stroke, Brain Infarction
Interventions
Eptifibatide, rt-PA
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 85 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Phase 2 Interventional Results available

A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients

NCT01282242
View directory record Official record
Conditions
Acute Stroke
Interventions
IV rt-PA
Drug
Lead sponsor
Lee Schwamm
Other
Eligibility
18 Years to 85 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Sep 8, 2026, 7:50 PM EDT
Terminated Phase 1 Interventional Results available

Thrombolysis in Pediatric Stroke (TIPS)

NCT01591096
View directory record Official record
Conditions
Stroke
Interventions
Tissue plasminogen activator (Activase®)
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
2 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Sep 8, 2026, 7:50 PM EDT
Terminated No phase listed Observational

Improving Patient Access to Stroke Therapy Study

NCT01870492
View directory record Official record
Conditions
Ischemic Stroke, Transient Ischemic Attack
Interventions
Activase, Endovascular therapy
Drug · Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 8, 2026, 7:50 PM EDT
Terminated Phase 1 Interventional Results available

Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer

NCT03300544
View directory record Official record
Conditions
Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Rectal Adenocarcinoma, Stage III Rectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IV Rectal Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
Interventions
Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Radiation Therapy, Talimogene Laherparepvec
Drug · Radiation · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Not applicable Interventional Results available

Safety Study of Post Intravenous tPA Monitoring in Ischemic Stroke

NCT02039375
View directory record Official record
Conditions
Stroke, Ischemic Stroke
Interventions
"Hopkins" post tPA for ischemic stroke monitoring protocol
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Sep 8, 2026, 7:50 PM EDT
Terminated Phase 2 Interventional

Evaluation of MST-188 in Acute Lower Limb Ischemia

NCT02093468
View directory record Official record
Conditions
Acute Limb Ischemia
Interventions
MST-188, Saline
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
4
States / cities
Little Rock, Arkansas • Tampa, Florida • Brooklyn, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Sep 8, 2026, 7:50 PM EDT